TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomized, Open Label Study Evaluating the Safety of Apixaban in Subjects With Cancer Related Venous Thromboembolism
Brief Summary: This randomized phase III trial studies the side effects of and compares apixaban and dalteparin in reducing blood clots in patients with cancer-related venous thromboembolism. Venous thromboembolism is a condition in which a blood clot forms in a vein and then breaks off and moves through the bloodstream. Patients with cancer are at increased risk for venous thromboembolism. Apixaban and dalteparin are drugs used to prevent blood clots from forming or to treat blood clots that have formed. It is not yet known whether apixaban or dalteparin is more effective in reducing blood clots in patients with cancer related venous thromboembolism.

ADAM-VTE


Options:
A: Arm Label: dabigatran etexilate 150 mg BID; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate 150 mg twice daily (BID) | Arm Label: matching placebo twice daily (BID); Type: PLACEBO_COMPARATOR; Interventions: Drug: matching placebo twice daily (BID) | Intervention Type: DRUG; Name: dabigatran etexilate 150 mg twice daily (BID); Assigned to Arm(s): dabigatran etexilate 150 mg BID | Intervention Type: DRUG; Name: matching placebo twice daily (BID); Assigned to Arm(s): matching placebo twice daily (BID)
B: Arm Label: Arm I (apixaban); Type: EXPERIMENTAL; Interventions: Drug: Apixaban, Other: Questionnaire Administration | Arm Label: Arm II (dalteparin); Type: EXPERIMENTAL; Interventions: Drug: Dalteparin, Other: Questionnaire Administration | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Arm I (apixaban) | Intervention Type: DRUG; Name: Dalteparin; Assigned to Arm(s): Arm II (dalteparin) | Intervention Type: OTHER; Name: Questionnaire Administration; Assigned to Arm(s): Arm I (apixaban), Arm II (dalteparin)
C: Arm Label: Dabigatran etexilate (150mg bid); Type: EXPERIMENTAL; Interventions: Drug: Dabigatran etexilate | Arm Label: Warfarin (INR 2.0-3.0); Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin (INR 2.0-3.0) | Intervention Type: DRUG; Name: Dabigatran etexilate; Assigned to Arm(s): Dabigatran etexilate (150mg bid)
D: Arm Label: Dabigatran; Type: EXPERIMENTAL; Interventions: Drug: Dabigatran | Arm Label: Warfarin (INR of 2.0-3.0); Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Dabigatran; Assigned to Arm(s): Dabigatran | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin (INR of 2.0-3.0)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomized, Open Label Study Evaluating the Safety of Apixaban in Subjects With Cancer Related Venous Thromboembolism
Brief Summary: This randomized phase III trial studies the side effects of and compares apixaban and dalteparin in reducing blood clots in patients with cancer-related venous thromboembolism. Venous thromboembolism is a condition in which a blood clot forms in a vein and then breaks off and moves through the bloodstream. Patients with cancer are at increased risk for venous thromboembolism. Apixaban and dalteparin are drugs used to prevent blood clots from forming or to treat blood clots that have formed. It is not yet known whether apixaban or dalteparin is more effective in reducing blood clots in patients with cancer related venous thromboembolism.

ADAM-VTE


Options:
A: Arm Label: Arm I (apixaban); Type: EXPERIMENTAL; Interventions: Drug: Apixaban, Other: Questionnaire Administration | Arm Label: Arm II (dalteparin); Type: EXPERIMENTAL; Interventions: Drug: Dalteparin, Other: Questionnaire Administration | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Arm I (apixaban) | Intervention Type: DRUG; Name: Dalteparin; Assigned to Arm(s): Arm II (dalteparin) | Intervention Type: OTHER; Name: Questionnaire Administration; Assigned to Arm(s): Arm I (apixaban), Arm II (dalteparin)
B: Arm Label: Apixaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin, Drug: warfarin, Drug: Placebo for apixaban | Arm Label: Enoxaparin + Warfarin; Type: EXPERIMENTAL; Interventions: Drug: Placebo for enoxaparin, Drug: Placebo for warfarin, Drug: apixaban | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Placebo for apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Placebo for enoxaparin; Assigned to Arm(s): Enoxaparin + Warfarin | Intervention Type: DRUG; Name: Placebo for warfarin; Assigned to Arm(s): Enoxaparin + Warfarin | Intervention Type: DRUG; Name: apixaban; Assigned to Arm(s): Enoxaparin + Warfarin
C: Arm Label: Apixaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban | Arm Label: Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Enoxaparin
D: Arm Label: dabigatran etexilate; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate | Arm Label: standard of care; Type: ACTIVE_COMPARATOR; Interventions: Drug: standard of care | Intervention Type: DRUG; Name: dabigatran etexilate; Assigned to Arm(s): dabigatran etexilate | Intervention Type: DRUG; Name: standard of care; Assigned to Arm(s): standard of care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomized, Open Label Study Evaluating the Safety of Apixaban in Subjects With Cancer Related Venous Thromboembolism
Brief Summary: This randomized phase III trial studies the side effects of and compares apixaban and dalteparin in reducing blood clots in patients with cancer-related venous thromboembolism. Venous thromboembolism is a condition in which a blood clot forms in a vein and then breaks off and moves through the bloodstream. Patients with cancer are at increased risk for venous thromboembolism. Apixaban and dalteparin are drugs used to prevent blood clots from forming or to treat blood clots that have formed. It is not yet known whether apixaban or dalteparin is more effective in reducing blood clots in patients with cancer related venous thromboembolism.

ADAM-VTE


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Unfractionated heparin | Arm Label: Arm 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Unfractionated heparin; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Arm 3
B: Arm Label: Dabigatran etexilate (150mg bid); Type: EXPERIMENTAL; Interventions: Drug: Dabigatran etexilate | Arm Label: Warfarin (INR 2.0-3.0); Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin (INR 2.0-3.0) | Intervention Type: DRUG; Name: Dabigatran etexilate; Assigned to Arm(s): Dabigatran etexilate (150mg bid)
C: Arm Label: Arm I (apixaban); Type: EXPERIMENTAL; Interventions: Drug: Apixaban, Other: Questionnaire Administration | Arm Label: Arm II (dalteparin); Type: EXPERIMENTAL; Interventions: Drug: Dalteparin, Other: Questionnaire Administration | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Arm I (apixaban) | Intervention Type: DRUG; Name: Dalteparin; Assigned to Arm(s): Arm II (dalteparin) | Intervention Type: OTHER; Name: Questionnaire Administration; Assigned to Arm(s): Arm I (apixaban), Arm II (dalteparin)
D: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Enoxaparin/VKA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin followed by VKA | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Enoxaparin followed by VKA; Assigned to Arm(s): Enoxaparin/VKA

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Brief Summary: This is a study to evaluate the hypothesis that FDA cleared thrombectomy devices plus medical management leads to superior clinical outcomes in acute ischemic stroke patients at 90 days when compared to medical management alone in appropriately selected subjects with the Target mismatch profile and an MCA (M1 segment) or ICA occlusion who can be randomized and have endovascular treatment initiated between 6-16 hours after last seen well.


Options:
A: Arm Label: intravenous (IV) rt-PA alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV rt-PA alone | Arm Label: Endovascular therapy; Type: EXPERIMENTAL; Interventions: Drug: IV rt-PA alone, Other: endovascular therapy | Intervention Type: DRUG; Name: IV rt-PA alone; Assigned to Arm(s): Endovascular therapy, intravenous (IV) rt-PA alone | Intervention Type: OTHER; Name: endovascular therapy; Assigned to Arm(s): Endovascular therapy
B: Arm Label: endovascular thrombectomy therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Endovascular Thrombectomy, Device: Trevo Retriever, Device: Solitaire™ FR Revascularization Device, Device: Penumbra thrombectomy system, Device: Covidien MindFrame Capture Revascularization Device | Arm Label: Medical Management; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Endovascular Thrombectomy; Assigned to Arm(s): endovascular thrombectomy therapy | Intervention Type: DEVICE; Name: Trevo Retriever; Assigned to Arm(s): endovascular thrombectomy therapy | Intervention Type: DEVICE; Name: Solitaire™ FR Revascularization Device; Assigned to Arm(s): endovascular thrombectomy therapy | Intervention Type: DEVICE; Name: Penumbra thrombectomy system; Assigned to Arm(s): endovascular thrombectomy therapy | Intervention Type: DEVICE; Name: Covidien MindFrame Capture Revascularization Device; Assigned to Arm(s): endovascular thrombectomy therapy
C: Arm Label: Trevo Thrombectomy Procedure; Type: EXPERIMENTAL; Interventions: Device: Trevo Thrombectomy Procedure, Other: Medical Management | Arm Label: Medical Management; Type: ACTIVE_COMPARATOR; Interventions: Other: Medical Management | Intervention Type: DEVICE; Name: Trevo Thrombectomy Procedure; Assigned to Arm(s): Trevo Thrombectomy Procedure | Intervention Type: OTHER; Name: Medical Management; Assigned to Arm(s): Medical Management, Trevo Thrombectomy Procedure
D: Arm Label: IA thrombolysis; Type: EXPERIMENTAL; Interventions: Other: Alteplase IA and/or mechanical thrombolysis | Arm Label: IV rtPA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Alteplase IV | Intervention Type: OTHER; Name: Alteplase IA and/or mechanical thrombolysis; Assigned to Arm(s): IA thrombolysis | Intervention Type: DRUG; Name: Alteplase IV; Assigned to Arm(s): IV rtPA

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Brief Summary: This is a study to evaluate the hypothesis that FDA cleared thrombectomy devices plus medical management leads to superior clinical outcomes in acute ischemic stroke patients at 90 days when compared to medical management alone in appropriately selected subjects with the Target mismatch profile and an MCA (M1 segment) or ICA occlusion who can be randomized and have endovascular treatment initiated between 6-16 hours after last seen well.


Options:
A: Arm Label: general anesthesia; Type: EXPERIMENTAL; Interventions: Drug: Etomidate, Drug: Succinylcholine, Drug: Propofol, Drug: Remifentanil | Arm Label: sedation; Type: EXPERIMENTAL; Interventions: Drug: Remifentanil, Drug: Lidocaine | Intervention Type: DRUG; Name: Etomidate; Assigned to Arm(s): general anesthesia | Intervention Type: DRUG; Name: Succinylcholine; Assigned to Arm(s): general anesthesia | Intervention Type: DRUG; Name: Propofol; Assigned to Arm(s): general anesthesia | Intervention Type: DRUG; Name: Remifentanil; Assigned to Arm(s): general anesthesia, sedation | Intervention Type: DRUG; Name: Lidocaine; Assigned to Arm(s): sedation
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Endovascular thrombectomy/thrombolysis; Type: EXPERIMENTAL; Interventions: Procedure: Endovascular thrombectomy/thrombolysis | Intervention Type: PROCEDURE; Name: Endovascular thrombectomy/thrombolysis; Assigned to Arm(s): Endovascular thrombectomy/thrombolysis
C: Arm Label: endovascular thrombectomy therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Endovascular Thrombectomy, Device: Trevo Retriever, Device: Solitaire™ FR Revascularization Device, Device: Penumbra thrombectomy system, Device: Covidien MindFrame Capture Revascularization Device | Arm Label: Medical Management; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Endovascular Thrombectomy; Assigned to Arm(s): endovascular thrombectomy therapy | Intervention Type: DEVICE; Name: Trevo Retriever; Assigned to Arm(s): endovascular thrombectomy therapy | Intervention Type: DEVICE; Name: Solitaire™ FR Revascularization Device; Assigned to Arm(s): endovascular thrombectomy therapy | Intervention Type: DEVICE; Name: Penumbra thrombectomy system; Assigned to Arm(s): endovascular thrombectomy therapy | Intervention Type: DEVICE; Name: Covidien MindFrame Capture Revascularization Device; Assigned to Arm(s): endovascular thrombectomy therapy
D: Arm Label: General anaesthesia; Type: ACTIVE_COMPARATOR; Interventions: Procedure: General anaesthesia | Arm Label: Conscious Sedation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Conscious Sedation | Intervention Type: PROCEDURE; Name: General anaesthesia; Assigned to Arm(s): General anaesthesia | Intervention Type: PROCEDURE; Name: Conscious Sedation; Assigned to Arm(s): Conscious Sedation

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Brief Summary: This is a study to evaluate the hypothesis that FDA cleared thrombectomy devices plus medical management leads to superior clinical outcomes in acute ischemic stroke patients at 90 days when compared to medical management alone in appropriately selected subjects with the Target mismatch profile and an MCA (M1 segment) or ICA occlusion who can be randomized and have endovascular treatment initiated between 6-16 hours after last seen well.


Options:
A: Arm Label: endovascular thrombectomy therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Endovascular Thrombectomy, Device: Trevo Retriever, Device: Solitaire™ FR Revascularization Device, Device: Penumbra thrombectomy system, Device: Covidien MindFrame Capture Revascularization Device | Arm Label: Medical Management; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Endovascular Thrombectomy; Assigned to Arm(s): endovascular thrombectomy therapy | Intervention Type: DEVICE; Name: Trevo Retriever; Assigned to Arm(s): endovascular thrombectomy therapy | Intervention Type: DEVICE; Name: Solitaire™ FR Revascularization Device; Assigned to Arm(s): endovascular thrombectomy therapy | Intervention Type: DEVICE; Name: Penumbra thrombectomy system; Assigned to Arm(s): endovascular thrombectomy therapy | Intervention Type: DEVICE; Name: Covidien MindFrame Capture Revascularization Device; Assigned to Arm(s): endovascular thrombectomy therapy
B: Arm Label: intravenous (IV) rt-PA alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV rt-PA alone | Arm Label: Endovascular therapy; Type: EXPERIMENTAL; Interventions: Drug: IV rt-PA alone, Other: endovascular therapy | Intervention Type: DRUG; Name: IV rt-PA alone; Assigned to Arm(s): Endovascular therapy, intravenous (IV) rt-PA alone | Intervention Type: OTHER; Name: endovascular therapy; Assigned to Arm(s): Endovascular therapy
C: Intervention Type: DRUG; Name: rt-PA 0.9 mg/kg verum or placebo Intravenous; Assigned to Arm(s): N/A
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Endovascular thrombectomy/thrombolysis; Type: EXPERIMENTAL; Interventions: Procedure: Endovascular thrombectomy/thrombolysis | Intervention Type: PROCEDURE; Name: Endovascular thrombectomy/thrombolysis; Assigned to Arm(s): Endovascular thrombectomy/thrombolysis

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Brief Summary: This is a study to evaluate the hypothesis that FDA cleared thrombectomy devices plus medical management leads to superior clinical outcomes in acute ischemic stroke patients at 90 days when compared to medical management alone in appropriately selected subjects with the Target mismatch profile and an MCA (M1 segment) or ICA occlusion who can be randomized and have endovascular treatment initiated between 6-16 hours after last seen well.


Options:
A: Arm Label: intravenous tissue plasminogen activator; Type: EXPERIMENTAL; Interventions: Drug: Tissue Plasminogen Activator (Alteplase) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tissue Plasminogen Activator (Alteplase); Assigned to Arm(s): intravenous tissue plasminogen activator | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: endovascular thrombectomy therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Endovascular Thrombectomy, Device: Trevo Retriever, Device: Solitaire™ FR Revascularization Device, Device: Penumbra thrombectomy system, Device: Covidien MindFrame Capture Revascularization Device | Arm Label: Medical Management; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Endovascular Thrombectomy; Assigned to Arm(s): endovascular thrombectomy therapy | Intervention Type: DEVICE; Name: Trevo Retriever; Assigned to Arm(s): endovascular thrombectomy therapy | Intervention Type: DEVICE; Name: Solitaire™ FR Revascularization Device; Assigned to Arm(s): endovascular thrombectomy therapy | Intervention Type: DEVICE; Name: Penumbra thrombectomy system; Assigned to Arm(s): endovascular thrombectomy therapy | Intervention Type: DEVICE; Name: Covidien MindFrame Capture Revascularization Device; Assigned to Arm(s): endovascular thrombectomy therapy
C: Arm Label: Group with endovascular treatment; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Rescue endovascular therapy | Arm Label: Group without endovascular treatment; Type: ACTIVE_COMPARATOR; Interventions: Procedure: No endovascular therapy | Intervention Type: PROCEDURE; Name: Rescue endovascular therapy; Assigned to Arm(s): Group with endovascular treatment | Intervention Type: PROCEDURE; Name: No endovascular therapy; Assigned to Arm(s): Group without endovascular treatment
D: Arm Label: Alteplase; Type: EXPERIMENTAL; Interventions: Drug: Tissue-type plasminogen activator (alteplase) | Arm Label: Standard Care; Type: OTHER; Interventions: Other: Standard care | Intervention Type: DRUG; Name: Tissue-type plasminogen activator (alteplase); Assigned to Arm(s): Alteplase | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Standard Care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of a Supervised Versus Non-supervised Exercise Program on Adherence and Functional Outcomes in Colorectal Cancer Patients
Brief Summary: Investigation into prehabilitation by increasing the supervision of exercise in patients undergoing colorectal resection for cancer and comparing with patients involved in a rehabilitation group receiving exercise after surgery.


Options:
A: Arm Label: Prehabilitation Plus; Type: ACTIVE_COMPARATOR; Interventions: Other: Prehabilitation Plus | Arm Label: Rehabilitation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Prehabilitation Plus; Assigned to Arm(s): Prehabilitation Plus
B: Arm Label: Prehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Prehabilitation | Arm Label: No-intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Prehabilitation; Assigned to Arm(s): Prehabilitation
C: Arm Label: Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise | Arm Label: Standard nutrition counselling; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise
D: Arm Label: HIT; Type: EXPERIMENTAL; Interventions: Procedure: HIT | Arm Label: MCT; Type: ACTIVE_COMPARATOR; Interventions: Procedure: MCT | Intervention Type: PROCEDURE; Name: HIT; Assigned to Arm(s): HIT | Intervention Type: PROCEDURE; Name: MCT; Assigned to Arm(s): MCT

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of a Supervised Versus Non-supervised Exercise Program on Adherence and Functional Outcomes in Colorectal Cancer Patients
Brief Summary: Investigation into prehabilitation by increasing the supervision of exercise in patients undergoing colorectal resection for cancer and comparing with patients involved in a rehabilitation group receiving exercise after surgery.


Options:
A: Arm Label: multimodal prehabilitation begun preop; Type: EXPERIMENTAL; Interventions: Behavioral: multimodal prehabilitation | Arm Label: Multimodal prehabilitation begun postop; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: multimodal prehabilitation | Intervention Type: BEHAVIORAL; Name: multimodal prehabilitation; Assigned to Arm(s): multimodal prehabilitation begun preop | Intervention Type: BEHAVIORAL; Name: multimodal prehabilitation; Assigned to Arm(s): Multimodal prehabilitation begun postop
B: Arm Label: Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise programme | Arm Label: No Exercise; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise programme; Assigned to Arm(s): Exercise
C: Arm Label: Pre-surgery physiotherapy; Type: OTHER; Interventions: Other: Pre-surgery physiotherapy | Arm Label: Waiting-list; Type: OTHER; Interventions: Other: Waiting-list | Intervention Type: OTHER; Name: Pre-surgery physiotherapy; Assigned to Arm(s): Pre-surgery physiotherapy | Intervention Type: OTHER; Name: Waiting-list; Assigned to Arm(s): Waiting-list
D: Arm Label: Prehabilitation Plus; Type: ACTIVE_COMPARATOR; Interventions: Other: Prehabilitation Plus | Arm Label: Rehabilitation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Prehabilitation Plus; Assigned to Arm(s): Prehabilitation Plus

Answer: D